Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Policy / Regulatory

AI in Healthcare: The Impact of DeepSeek Technology and Industry Developments

Fineline Cube Feb 23, 2025

The integration of advanced AI technologies into healthcare is revolutionizing the industry, and the recent...

Policy / Regulatory

In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications

Fineline Cube Feb 22, 2025

The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...

Policy / Regulatory

State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms

Fineline Cube Feb 22, 2025

The State Council has released a second draft proposal outlining measures to support the high-quality...

Company Medical Device

Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing

Fineline Cube Feb 22, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing...

Policy / Regulatory

Shanghai Issues Legal Guidebook for Innovative Drug Marketing

Fineline Cube Feb 22, 2025

The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...

Policy / Regulatory

China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation

Fineline Cube Feb 22, 2025

The Chinese government has released a set of opinions detailing the establishment of a new...

Company Drug

Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma

Fineline Cube Feb 21, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...

Company Drug

GSK’s Nucala Receives NMPA Review for COPD Treatment

Fineline Cube Feb 21, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE

Fineline Cube Feb 21, 2025

According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...

Company

Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY

Fineline Cube Feb 21, 2025

Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...

Company Deals Medical Device

Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech

Fineline Cube Feb 21, 2025

Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and...

Company Deals

Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies

Fineline Cube Feb 21, 2025

Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...

Company Drug

Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study

Fineline Cube Feb 21, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...

Company Drug

Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval

Fineline Cube Feb 21, 2025

China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...

Company Deals

Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development

Fineline Cube Feb 21, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...

Company Drug

Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis

Fineline Cube Feb 21, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...

Company Deals

FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included

Fineline Cube Feb 21, 2025

US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...

Company Deals

Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem

Fineline Cube Feb 21, 2025

China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...

Company Drug

Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931

Fineline Cube Feb 21, 2025

German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...

Company Drug

Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review

Fineline Cube Feb 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Posts pagination

1 … 233 234 235 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.